Floatz logo

T-Dxd

Breast Cancer, Estrogen Receptor-Positive

Guangzhou Women and Children's Medical Centerantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

76 Active assets in the Breast Cancer, Estrogen Receptor-Positive cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Abemaciclib
Jonsson Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

T-Dxd is also rated in:

HER2 positive breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →
Breast NeoplasmsDormant
B
Indicative ·
56 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →